N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors
The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.
1. A compound that is
2. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.
3. A method of treating hereditary angioedema comprising administering to a subject in need thereof the compound of claim 1 .
4. A pharmaceutically acceptable salt of the compound
5. A pharmaceutical composition comprising the pharmaceutically acceptable salt of claim 4 and a pharmaceutically acceptable carrier, diluent or excipient.
6. A method of treating hereditary angioedema comprising administering to a subject in need thereof the pharmaceutically acceptable salt of claim 4 .
7. A pharmaceutically acceptable solvate of the compound
8. A pharmaceutical composition comprising the pharmaceutically acceptable solvate of claim 7 and a pharmaceutically acceptable carrier, diluent or excipient.
9. A method of treating hereditary angioedema comprising administering to a subject in need thereof the pharmaceutically acceptable solvate of claim 7 .
10. A pharmaceutically acceptable hydrate of the compound
11. A pharmaceutical composition comprising the pharmaceutically acceptable hydrate of claim 10 and a pharmaceutically acceptable carrier, diluent or excipient.
12. A method of treating hereditary angioedema comprising administering to a subject in need thereof the pharmaceutically acceptable hydrate of claim 10 .
13. A pharmaceutically acceptable solvate of a pharmaceutically acceptable salt of the compound
14. A pharmaceutical composition comprising the pharmaceutically acceptable solvate of claim 13 and a pharmaceutically acceptable carrier, diluent or excipient.
15. A method of treating hereditary angioedema comprising administering to a subject in need thereof the pharmaceutically acceptable solvate of claim 13 .